Advertisement

European Journal of Dermatology

, Volume 27, Issue 6, pp 671–673 | Cite as

Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy

  • David Aguiar-BujandaEmail author
  • Arancha Dueñas-Comino
  • Camila Cabello
  • Jesus Bastida
  • José Carlos Rivero-Vera
  • Miguel Angel Limeres-González
Correspondence
  • 20 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995; 13: 1343–54.CrossRefGoogle Scholar
  2. 2.
    Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term followup data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653–61.CrossRefGoogle Scholar
  3. 3.
    Gravanis I, Tzogani K, van Hennik P, et al. The European Medicines Agency review of brentuximab vedotin (Adcetris) for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Oncologist 2016; 21: 102–9.CrossRefGoogle Scholar
  4. 4.
    Hernandez C, Puangsuvan SN, Peterson A, Robinson JK. Localized perineal cutaneous nodules: a case of recurrent systemic anaplastic large-cell lymphoma. Clin Exp Dermatol 2009; 34: e722–5.CrossRefGoogle Scholar
  5. 5.
    Nambudiri VE, Aboutalebi A, Granter SR, Saavedra A. Recurrent ALK-negative anaplastic large T-cell lymphoma presenting as necrotizing vasculitis. Am J Dermatopathol 2013; 35: 512–6.CrossRefGoogle Scholar
  6. 6.
    Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496–504.CrossRefGoogle Scholar
  7. 7.
    Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012; 120: 2280–9.CrossRefGoogle Scholar
  8. 8.
    Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014; 124: 1473–80.CrossRefGoogle Scholar
  9. 9.
    Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017. Ahead of print.Google Scholar

Copyright information

© JLE/Springer 2018

Authors and Affiliations

  • David Aguiar-Bujanda
    • 1
    Email author
  • Arancha Dueñas-Comino
    • 1
  • Camila Cabello
    • 2
  • Jesus Bastida
    • 2
  • José Carlos Rivero-Vera
    • 3
  • Miguel Angel Limeres-González
    • 3
  1. 1.Medical OncologyHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran CanariaLas PalmasSpain
  2. 2.DermatologyHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran CanariaLas PalmasSpain
  3. 3.PathologyHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran CanariaLas PalmasSpain

Personalised recommendations